Team:Aix-Marseille/Model

Engineered M13 modelling


In order to produce PLPs, both M13KO7 (produces all the phage proteins) and the phagemid (containing the toxin gene) need to be integrated into E.coli. During the process, if p5 packages M13KO7 it will produce a replicative phage and if it packages our phagemid it will produce PLPs.

With our project, KILL XYL we set to engineer a cure against the disease caused by the plant pathogen Xylella fastidiosa. One of our approaches is to engineer phage-like particles (PLPs), that will deliver toxic genes into the bacterium. Phage systems, like M13, have been employed in biotechnological applications, most prominently in the identification and maturation of medically-relevant binding molecules through phage display [1].

However, production of phages such as M13 has longterm consequences in E. coli, especially regarding metabolism[2]. M13 has a particular life-cycle among phages: it is neither a virulent nor a temperate phage but rather engages in chronic infection. One of the crucial events of it's multiplication is the packaging of its own DNA in the capsid. To do so, M13's protein 5 (p5) targets M13 origin of replication (M13ori) and packages the single-strand DNA. This step is crucial to initiate formation of the phage particle. Afterwards, an assembly complex (made of proteins p1, p4 and p11) assembles the capsid (made of proteins p3, p6, p7, p8, p9) around the ssDNA.

One of the major reasons we chose to use phage-like particles (PLPs) was for our device to be non replicative, so as to prevent the spread of GMOs in the environnement. We designed these PLPs by modifying M13's genome to prevent replication and the addition of a phagemid in the factory cell E.coli. Therefore, to create PLPs we use a modified M13 genome (M13KO7) that has several genes inserts in it M13ori and we integrate a phagemid with a M13ori.

Thanks to Jacques VAN HELDEN interview we put attention to the risk of recombination between M13KO7 and the phagemid. This question matter because we aim to create PLPs that aren't able to replicate and thus spread in the environment. Therefore, we test this possibility along our wetlab tests.

Here we wanted to answer a single question: As p5 recognized M13ori, will the bacterium produces only PLPs or will it also produces replicative phages ?.

Introduction

Modelling is an essential aspect of engineering, and we wanted to engineer a novel specific phage targeted to Xylella fastidiosa. Apart from a preliminary exercise model used to test our understanding of our system, most of our work was done using a (heavily) adapted version of an already published model of M13 physiology. Modelling allows engineers to explore several avenues of research very quickly and to discard those less likely to succeed early on and at all stages of prototyping and development. For this back and forth betwen wet- and dry-lab to be meaningfull, it needs to be validated against preliminary data, which we did by ensuring our model fitted experimental particle profiles obtained by the wetlab team. We then investigated wether levels of certain key proteins changed particle composition, before determining the ideal number of plasmid copies to optimize our production for the wetlab team.

2 plasmides

p5 incorpore ssDNA

p3 p6 prot de "terminaison" du phage


Our model

After learning the ropes using an overly simplified model, we decided to adopt the model of a "wild-type" M13's biology [2][3] to fit our own engineered version of M13 and better inform wet lab experiments, as well as explain some of their preliminary findings!

Smeal's et al model describes the whole physiology of M13 in an infected cell. We conserved the parts of their model which deals with cellular processes such as DNA replication and transcription as well as protein translation, as there is no reason to think our design would affect these processes in a significant manner since those are physiological cellular processes.

However, we heavily altered the parts describing the interactions between the phage's proteins and genetic elements, since these are the diverging points between our construct and the wild-type M13. We accounted for the presence of two plasmids: M13KO7 and the lethal phagemid to be packaged, which fits our design by incorporating all the related pathways. We adapted the parameters to account for the differences between our constructs and wild-type M13. We also accounted for the possibility, in case of insufficient p3 or p6 concentrations, for the capsid to incorporate another plasmid. This translated by adding another step between capsid formation and phage release.

Model validation

We used the model we devised to predict a particule profile (i.e. ratio of replicative phages vs. PLPs) compared it to the particle profile obtained in wetlab:

T--Aix-Marseille--Recombination.png

This can perhaps be explained by two phenomena: 1) Our test method would label phages containing both M13KO7 and the phagemid as replicative phages. Perhaps several plasmids are incorporated in each particle, which would explain these results. See "Insufficient p3 and p6" for further exploration of this topic. 2) Even when deleting the extra step allowing the capsid to incorporate several plasmids, we obtain 2/3 replicative particles and 1/3 PLPs. See "Ideal number of plasmid copies" for further exploration of the phenomena.

Insufficient p3 and p6

P3 and p6 are proteins on the end of the capsid, which they "close", thereby provoking the liberation of the phage (or PLP) from the cell membrane.

Ideal number of plasmid copies

Our Human Practice research makes it very clear our device cannot be replicative if it is to be used outside of the lab. We want to know the ideal number of plasmid copies to optimize production of PLPs over phages.

Our results show that, counter-intuitively, a higher-copy plasmid is actually less likely to be incorporated into a particle. We hypothesize this is because a higher-copy plasmid's ORI recruits DNA polymerase with more efficiency, which diminishes available ssDNA for p5 to bind to and form particles with.

We would therefore suggest to engineer a phagemid based on a lower-copy backbone, such as pSC101, to optimize production of PLPs

Wet-lab and dry-lab back and forth

Materials and Methods

Our modelling was done using Matlab's Simbiology. The full .sbproj file (Simbiology file) can be found here.

Major parameters adaptation

Polymerase binding event: 2 times as likely to bind to phagemid (pUC ori) as opposed to M13KO7 (p15A ori). This parameter was chosen because it conducted to copy numbers best fitting known ratios in the absence of incorporation into phage particles.[4]


References

  1. ↑ Salmond, G. P. C. & Fineran, P. C. A century of the phage: past, present and future. Nat Rev Micro 13, 777–786 (2015).
  2. ↑ 2.0 2.1 Smeal et al, Simulation of the M13 life cycle I: Assembly of a genetically-structured deterministic chemical kinetic simulation, Virology, 500, January 2017
  3. ↑ Smeal et al, Simulation of the M13 life cycle II: Investigation of the control mechanisms of M13 infection and establishment of the carrier state, Virology, 500, January 2017
  4. ↑ http://blog.addgene.org/plasmid-101-origin-of-replication